Wrist-Worn nerve stimulator aims to tame atrial fibrillation after ablation
NCT ID NCT06748157
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a wrist-worn device called CardiaCare RR2 that stimulates the median nerve to calm irregular heart rhythms after catheter ablation for atrial fibrillation (AF). About 34 adults who have had AF ablation will use the device daily for six months. Half will receive active stimulation, the other half a sham device. The goal is to see if this non-invasive approach can reduce early and later recurrences of AF and related symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CardiaCare RR2 wrist-worn nerve stimulator
What this could lead to
If effective, this non-invasive device could help prevent atrial fibrillation recurrences after ablation without drugs or additional procedures.
What could go wrong
This is a small early-stage trial with only 34 participants. The device may not reduce arrhythmias, and some people may experience discomfort from the stimulation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States